Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03497637

Comparison of Vessel-FFR Versus FFR in Intermediate Coronary Stenoses

This is a prospective, randomized, controlled, multicenter, open-label study designed to assess whether vFFR is non-inferior to FFR in assessment of intermediate coronary stenosis in terms of the occurrence of MACE during 12 months after randomization.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Heart Center Dresden - University Clinic, Dresden, Germany

Loading trial locations.

About this study

Coronary angiography is insensitive to assess the physiologic significance of a coronary stenosis. Therefore, clinical guidelines support the use of pressure-derived fractional flow reserve (FFR) to assess the hemodynamic significance of coronary stenosis. Nevertheless, the penetration of FFR in clinical routine continues to be limited by its requirement for pharmacological vasodilation, prolonged procedure time and adverse systemic effects from adenosine.

Vessel-FFR (vFFR) is a novel method for evaluating the functional significance of coronary stenosis by calculation of the pressure drop in the vessel based on computation of two angiographic projections. The vFFR values at each point along the vessel are color-coded and superimposed on the 3D epicardial model and cut-off values of ≤0.80 identical to standard invasive FFR apply.

These developments may translate towards more physiology guided intervention bearing the potential to improve clinical outcomes in patients with stable CAD. The ability to derive FFR values from routinely performed coronary angiograms, without the practical drawbacks that limit invasive techniques, could have an important impact on daily clinical practice.

To date no randomized outcome-based clinical trial has compared an image-based FFR methodology with standard invasive FFR in terms of subsequent clinical outcomes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age >18 years
  • Willing to participate and able to understand, read and sign the informed consent document before the planned procedure
  • Eligible for coronary angiography and/or PCI
  • Coronary artery disease in one or more native major epicardial vessels or their branches by coronary angiogram with visually assessed de novo coronary stenosis in which the physiological severity of the lesion is in question (typically 40-80% diameter stenosis).
  • Stable angina or acute coronary syndrome (non-culprit vessels only and outside of primary intervention during acute STEMI or NSTE-ACS)
  • Participation in another interventional study

Exclusion criteria

  • Previous CABG with patent grafts to the interrogated vessel
  • Tandem stenoses separated by more than 10 mm that require separate pressure guide wire interrogation or PCI (not to be interrogated or treated as a single stenosis)
  • Total coronary occlusions
  • Hemodynamic instability (Killip class III-IV)
  • Heavily calcified or tortuous vessels
  • Terminal disease with life expectancy of less than 12 months
  • STEMI within 48 hours of procedure
  • Severe valvular heart disease
  • ACS patients with difficulty in assessing which the culprit lesion is
  • Significant contraindication to adenosine administration (e.g. Asthma bronchiale)
  • Pregnancy

Treatment and study plan

measurement of FFR

Diagnostic Test

use of pressure-derived FFR to assess the hemodynamic significance of coronary stenoses

measurement of Pd/Pa

Diagnostic Test

use of resting distal coronary pressure to aortic pressure ratio (Pd/Pa) to assess the hemodynamic significance of coronary stenoses

Primary outcomes

  1. Major Adverse Cardiac Event (MACE) rate

    Time frame: 1 year

    composite of cardiac death, non-fatal myocardial infarction or unplanned revascularization

Secondary outcomes

  1. MACE during long-term follow-up

    Time frame: 2 and 5 years

  2. Each component of the primary endpoint assessed by structured telephone interview and verification by hospital reports

    Time frame: 1, 2 and 5 years

  3. Repeat revascularization (PCI or CABG) assessed by structured telephone interview and verification by hospital reports in case of event

    Time frame: 1, 2 and 5 years

  4. All-cause mortality

    Time frame: 1, 2 and 5 years

  5. Cross-over rate from the one strategy to the other

    Time frame: at intervention

  6. Number of analyzable lesions in both treatment arms

    Time frame: at intervention

Study contacts

Contact information is provided by the study sponsor or research team.

Holger Thiele, MD

CONTACT

[email protected]

+49 341 865 1428

Sponsors and collaborators

Lead sponsor

Helios Health Institute GmbH

Other

Collaborators

  • Heart Center Leipzig - University Hospital

Registry information

Official study title

Comparison of Non-Invasive Vessel Fractional Flow Reserve Calculated From Angiographic Images Versus Fractional Flow Reserve in Patients With Intermediate Coronary Artery Stenoses

Acronym: LIPSIASTRATEGY

Important dates

Study start
2020
Primary completion
2026
Study completion
2026
First posted
Apr 13, 2018
Registry last updated
Nov 25, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.